APA

Henrotin Y., Gharbi M., Dierckxsens Y., Priem F., Marty M., Seidel L., Albert A., Heuse E., Bonnet V. & Castermans C. (20150428). Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. : BMC complementary and alternative medicine.

Chicago

Henrotin Yves, Gharbi Myriam, Dierckxsens Yvan, Priem Fabian, Marty Marc, Seidel Laurence, Albert Adelin, Heuse Elisabeth, Bonnet Valérie and Castermans Caroline. 20150428. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. : BMC complementary and alternative medicine.

Harvard

Henrotin Y., Gharbi M., Dierckxsens Y., Priem F., Marty M., Seidel L., Albert A., Heuse E., Bonnet V. and Castermans C. (20150428). Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. : BMC complementary and alternative medicine.

MLA

Henrotin Yves, Gharbi Myriam, Dierckxsens Yvan, Priem Fabian, Marty Marc, Seidel Laurence, Albert Adelin, Heuse Elisabeth, Bonnet Valérie and Castermans Caroline. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. : BMC complementary and alternative medicine. 20150428.